We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Method Tests for Cystic Fibrosis Infection Pathogens

By LabMedica International staff writers
Posted on 31 Mar 2015
A new method of testing the most common cause of life-threatening infection in people with cystic fibrosis could improve efforts to study and combat the illness.

Cystic fibrosis is a serious genetic disease that causes recurring lung infections, bacteria colonize a patient's lungs, usually beginning in childhood, leading to difficulty breathing. More...
One of the most dangerous of these bacteria is Pseudomonas aeruginosa, which, within the unique mucus that forms in the lungs of a person with cystic fibrosis, develops into large, antibiotic-resistant colonies.

Scientists at the University of Texas (Austin, TX, USA) applied new technology to bacteria thriving in actual samples of the mucus from cystic fibrosis (CF) lungs to model the behavior of the bacterium in that environment. The team was then able to test tens of thousands of mutations of two strains of P. aeruginosa, which helped them identify key ways the pathogen behaves during an infection and the genes that might be essential for reproduction.

The new model allows scientists to run large-scale studies in conditions that are much more like the actual places where the bacteria colonize, without requiring scientists to collect countless specimens of actual mucus, called sputum, from humans. The ability to re-create conditions closer to the sputum in the lung of a CF patient will lead to better understanding of how different strains of the bacterium behave. It will also allow for easier identification of genes that contribute to the bacteria's spread from patient to patient, and more meaningful scientific trials to understand the bacteria’s resistance to antibiotics or identify new antimicrobial compounds that target specific genes necessary for maintaining these persistent infections.

John LiPuma, MD, a professor of pediatrics and epidemiology, said, “For the past decade, we have understood that Pseudomonas is arguably the major colonizing infection for people with cystic fibrosis. For a long time we have studied Pseudomonas the way we study other pathogens, but the cystic fibrosis lung is extraordinarily complex. In the scientific community, we've got to develop systems biology approaches, such as this one, that take a more sophisticated approach to get us where we need to be.” The study was published on March 16, 2015, in the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS).

Related Links:

University of Texas



Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Hemodynamic System Monitor
OptoMonitor
Gold Member
Hematology Analyzer
Medonic M32B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: AI blood-based cell-free DNA analyses detect early liver fibrosis and other diseases (Photo courtesy of Shutterstock)

AI-Based Liquid Biopsy Detects Liver Fibrosis, Cirrhosis and Chronic Disease Signals

Liver fibrosis and cirrhosis often develop silently for years before symptoms appear, making early diagnosis difficult. Detecting these conditions earlier could allow treatment before irreversible damage... Read more

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The addition of Biocare’s complementary IHC antibody, reagent and instrument portfolio enhances Agilent’s immunohistochemistry offering (Photo courtesy of Biocare Medical)

Agilent Technologies Acquires Pathology Diagnostics Company Biocare Medical

Agilent Technologies (Santa Clara, CA, USA) has entered into a definitive agreement to acquire Biocare Medical (Pacheco, CA, USA), expanding its pathology portfolio through the addition of highly complementary... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.